Atrial Fibrillation Clinical Trial
— STATICHOfficial title:
Study of Antithrombotic Treatment After IntraCerebral Haemorrhage
The study evaluates the effects of antithrombotic drugs (anticoagulant drugs or antiplatelet drugs) for prevention of ischaemic events in patients With recent intracerebral haemorrhage.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | June 2031 |
Est. primary completion date | June 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient age =18 years. - Spontaneous, primary ICH, of =1 day, but not more than 180 days after onset of qualifying ICH, i.e.: - No preceding traumatic brain injury, based on history from the patient/witness of spontaneous symptom onset, and brain imaging appearances consistent of spontaneous ICH (i.e. any brain/bone/soft tissue appearances of trauma must have occurred secondary to a spontaneous ICH) - No 'secondary' or underlying structural cause (e.g. haemorrhagic transformation of an ischaemic stroke, aneurysm, tumour, arteriovenous malformation, or intracerebral venous thrombosis) - Patient have indication for antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of ischaemic events, either antiplatelet drugs (for patients with vascular disease), or anticoagulant drug for patients with atrial fibrillation. - Consent to randomisation from the patient (or personal / legal / professional representative if the patient does not have mental capacity). - MRI (or CT) is performed before randomisation. Exclusion Criteria: - Clear indication for antiplatelet or anticoagulant treatment (e.g. prosthetic heart valves). - Contraindications to the antithrombotic drug that will be administered. - Patient is pregnant, breastfeeding, or of childbearing age and not taking contraception. - For patients examined with MRI: Contraindication for brain MRI - Malignancy with life expectancy less than 2 years |
Country | Name | City | State |
---|---|---|---|
Denmark | Herlev Gentofte Hospital | Copenhagen | |
Norway | Oslo University Hospital | Oslo | |
Sweden | Umeå University Hospital | Umeå |
Lead Sponsor | Collaborator |
---|---|
Oslo University Hospital |
Denmark, Norway, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fatal or non-fatal symptomatic ICH. | Neurological deterioration or death associated with intracerebral haemorrhage found on CT scan, MRI, or autopsy. | 2 years | |
Secondary | Functional outcome | Modified Rankin Scale score | 2 years | |
Secondary | Death of any cause | Death of any cause | 2 years | |
Secondary | Vascular death | Death of vascular cause | 2 years | |
Secondary | Symptomatic epidural, subdural, or subarachnoid haemorrhage | Neurological deterioration or death associated with epidural, subdural, or subarachnoid haemorrhage found on CT scan, MRI, or autopsy. | 2 years | |
Secondary | Symptomatic major extracranial haemorrhage | Clinically overt bleeding associated with one or more of:
Transfusion of >2 red cell units of blood A fall in haemoglobin of 2 g/dL, (1.24 mmol/L) Bleeding into retroperitoneum, intraocular space or major joint Bleeding leading to permanent treatment cessation |
2 years | |
Secondary | Ischaemic events | Transient ischaemic attack, ischaemic stroke, unstable angina, acute myocardial infarction (type 1), peripheral arterial occlusion, mesenteric ischaemia, retinal arterial occlusion, deep vein thrombosis or pulmonary embolism. | 2 years | |
Secondary | Cognitive outcome at two years | Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |